Abstract
Beta-lactam antibiotics comprise 8-20% of all self-reported medication allergies. Antibiotic allergy misidentification is detrimental since broad-spectrum alternatives can lead to suboptimal treatment and potentiate resistance. The multidisciplinary Beta-lactam Allergy Assessment and Skin Testing (BLAAST) program was implemented to facilitate comprehensive allergy history documentation and increase use of targeted beta-lactams. The study objective was to assess rates of complete allergy histories and beta-lactam days of therapy (DOT-BL) per 1,000 days-present before versus after program implementation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
